Brian Jonas
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Brian Jonas sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Brian Jonas: 4 sponsored US clinical trials, 2 recruiting.
Brian Jonas sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Anemia With Excess Blasts in Transformation, with 1 trials.
Upper-quartile sponsor footprint
Brian Jonas sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
NCT04905810
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
NCT02997761
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
NCT04964505
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
NCT02553941
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Brian Jonas pipeline
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Refractory Anemia With Excess Blasts in Transformation (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Brian Jonas: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Brian Jonas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Brian Jonas page
4 registered trials is a research-attention snapshot, not an endorsement of Brian Jonas or any single study.
- 2 of Brian Jonas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Refractory Anemia With Excess Blasts in Transformation is the condition Brian Jonas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Anemia With Excess Blasts in Transformation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Brian Jonas pipeline card: 4 registered trials from official public datasets.Report a data error.